



Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills
Hyderabad – 500 034, Telangana, India

CIN: L85195TG1984PLC004507

Tel: + 91 40 4900 2900

Fax: + 91 40 4900 2999

Email: mail@drreddys.com

Web: www.drreddys.com

July 22, 2026

National Stock Exchange of India Ltd. (Scrip Code: DRREDDY)

BSE Limited. (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Q1 FY27 Unaudited Financial Results Presentation

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the presentation on the Unaudited Financial Results of the Company for the quarter ended June 30, 2026.

This is for your information and records.

Thanking you.

Yours faithfully,

For **Dr. Reddy's Laboratories Limited**

K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR

Encl: as above



Dr. Reddy's

Q1FY27 RESULTS UPDATE

22 JULY 2026

Safe Harbor Statement

This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as “anticipates”, “believes”, “estimates”, “expects”, “intends”, “plans”, “predicts”, “projects” and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- General economic and business conditions in India and other key global markets in which we operate;
- The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;
- Changes in the value of the Rupee and other currency changes;
- Changes in the Indian and international interest rates;
- Allocations of funds by the Governments in our key global markets;
- Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and
- Changes in political conditions in India and in our key global markets.

Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements.

For more detailed information on the risks and uncertainties associated with the Company's business activities, please see the company's annual report filed in Form 20-F with the US SEC for the fiscal year ended March 31, 2026, and our other filings with US SEC. Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events.

Q1FY27 Financial Highlights

Healthy double-digit base business^ growth; EBITDA Margin @15.4% before semaglutide related impact

Reported Revenues

₹ 8,071 Cr

↓ 6% YoY ↑ 7% QoQ

EBITDA | EBITDA %

₹ 1,009 Cr | 12.5%

↓ 56% YoY ↑ 3% QoQ

PBT | PBT %

₹ 553 Cr | 6.8%

↓ 71% YoY ↑ 178% QoQ


*PAT | PAT %

₹ 443 Cr | 5.5%

↓ 69% YoY ↑ 101% QoQ

**Attributable to Equity shareholders*

FINANCIALS EXCLUDING SEMAGLUTIDE API RELATED IMPACT



Financials excluding semaglutide Impact
Semaglutide API related impact
As reported

^Excluding Lenalidomide

- **Semaglutide API** related impact of ₹ 240 Cr, including inventory provision and other associated costs.
- EBITDA margin further impacted by higher solvent and freight cost arising from **Middle East conflict**
- **Reported RoCE @5.3%. Excluding semaglutide API impact, RoCE @8%.**
- **Net Cash** surplus at ₹3,058 Cr.

Q1FY27 Business Highlights

Continued progress across strategic priorities



- **First-to-market launch** in the US of anti-cancer drug, **bosutinib** 400mg, with a 180-day exclusivity.
- Dr. Reddy's becomes **1st company** to launch generic **semaglutide** injection for Type 2 Diabetes in **Canada**
- Launched **generic semaglutide tablets** in India.
- Launched nutrition offerings, **Celevida GLP+**, through our collaboration with Nestlé.
- **Toripalimab**, novel in-licensed oncology drug, entered **₹100 crore club** in <2 years of launch in India.
- Partnered with Innoviva Specialty Therapeutics to develop and commercialise, **XACDURO®**, a critical-care antibiotic, across select emerging markets.
- **Fast Track Designation** granted by USFDA for partnered product, **COYA 302**, for ALS treatment.
- Filed Marketing Authorisation Application for **abatacept** IV presentation with European Medicines Agency for Europe.



ZYTORVI™
toripalimab-tpzi injection
240mg/60mL (4mg/mL)

XACDURO®
(sulbactam for injection;
durlobactam for injection),
co-packaged for intravenous use

Q1FY27 Other Highlights

ESG

- Celebrated 25 years of **NYSE** listing, as the 1st and only Indian pharmaceutical company listed on the exchange.
- Placed in the **top 1% globally** by **FTSE Russell**.
- Ranked 165th globally among **TIME–Statista World's Most Sustainable Companies**, 5th among Indian companies.



OTHER UPDATES


- Received a Form 483 with **7 observations**, following a **PLI** at **biologics** facility, Bachupally in Jun '26, responded within the timeline.
- Certain batches of **semaglutide** were found to be out of specification due to an issue associated with the API.



Q1FY27 Revenue Split


Double-digit base business growth across all geographies, aided by forex, offset by lower lenalidomide sales

REVENUE BY SEGMENT



Branded businesses (India, Emerging Markets & NRT) account for 52% of revenues

GLOBAL GENERICS SPLIT




Key Financial Metrics

Sustaining growth & profitability, while investing for the future

REVENUES


(₹ Cr)



*Excl. lenalidomide shelf stock adjustment (SSA), Q4 revenues ₹7,969Cr

GROSS MARGINS

(% of Revenues)




*49.4% excl. sema API related impact

^48% excl. SSA

SG&A


(% of Revenues)



*Excl. VAT liability, 33.4% of revenues excl. SSA

R&D


(% of Revenues)



*Excl. CAR-T charge, 6.8% of revenues excl. SSA

EBITDA MARGINS

(% of Revenues)




*15.4% excl. sema API related impact

^19.5%, excl. SSA, CAR-T charge, VAT liability
#24.8%, excl. provision related to new Labour Codes in India


DILUTED EPS

(₹)



RoCE (Annualized)

(%)




*8% excl. sema API related impact

^17.5%, excl. SSA, Impairment of CAR-T & Eftilagimod Alfa, VAT liability


CAPEX

(₹ Cr)




CASH FLOW

(₹ Cr)



*Before acquisition related payouts


NET DEBT / EQUITY



^Net Surplus (Adjusted for non-current cash & borrowings) stood at ₹ 3,058 Cr as on 30 Jun '26

Q1FY27 North America Performance

Double digit growth in base business, impacted by lower lenalidomide sales




Revenues

₹ 2,205 cr

↓ 35%YoY ↑ 26%QoQ

Declined YoY due to lower lenalidomide sales.
Excluding shelf stock adjustment in Q4FY26,
declined 5% QoQ

Historical Revenues (₹ Cr)



*Includes impact of lenalidomide SSA of ₹453Cr

MARKET PERFORMANCE

10.3% vs 2.1%

DRL Growth vs US Generics Market
(Excl. Lenalidomide)
*As per IQVIA MAT Jun' 26

NEW LAUNCHES

6
Q1FY27

NEW ANDA | NDA FILINGS

5 | 1
Q1FY27

PRICE EROSION

MODERATE

PENDING APPROVAL

76 3
ANDAs NDAs
Includes 46 Para IVs & 24 FTFs
As of Jun'26




KEY UPDATES

- Double digit base business growth in Q1FY27, aided by new product launches and volumes.
- First company to secure approval and launch generic semaglutide injection for Type 2 Diabetes in **Canada**.
- First-to-market launch of anti-cancer drug, **bosutinib** 400mg, with a 180-day generic drug exclusivity.
- Launched **nintedanib**, a complex generic drug used in the treatment of lung diseases




Q1FY27 Emerging Markets Performance

Growth driven by new product launches across countries, supported by favourable forex



Q1FY27 India Performance

Consistent double-digit growth and IPM outperformance




Revenues

₹ 1,718 cr

↑ 17%YoY ↑ 10%QoQ

Growth Drivers : New brand launches including innovative assets & acquired portfolios, price increases and higher volumes.

Historical Revenues (₹ Cr)



MARKET PERFORMANCE*

14.6% vs 13.5%

*DRL MQT Growth vs IPM (Jun'26)

IPM RANK

#9 #10
FTM & MQT MAT
Jun'26 Jun'26

THERAPY LEADERHIP*

#1 #2
STOMATOLOGICALS VACCINES

NEW BRAND LAUNCHES

7
Q1FY27

₹100 CR+* BRANDS IN
BRANDS IPM TOP 300*
25 15

*As per IQVIA MAT Jun' 26

KEY UPDATES


- Launched **generic semaglutide tablets** in India.
- Launched nutrition offerings, **Celevida GLP+**, through our collaboration with Nestlé.
- Toripalimab**, novel in-licensed oncology drug, entered ₹100 crore club in less than 2 years of launch.



ZYTORVI
toripalimab-tpzi injection
240mg/5mL (8mg/mL)

Q1FY27 Europe Performance

Generics launches and forex tailwinds, offset by pricing pressure and NRT operating model changes



Revenues

₹ 1,444 Cr

↑ 13%YoY ↓ 0.6%QoQ

Growth Drivers : New product launches, favourable forex, offset by price erosion and change in gross-to-net following NRT integration

Historical Revenues (₹ Cr)

Q1FY27	1,444
Q4FY26	1,452
Q3FY26	1,448
Q2FY26	1,376
Q1FY26	1,274

EU COUNTRIES
PRESENT IN
21

NEW GX PRODUCT
LAUNCHES

24
Q1FY27


NEW FILINGS

1
Q1FY27

KEY UPDATES

- **NRT revenues** declined due to change in operating model post integration, where rebates & discounts to distributors offered, versus sales managed by seller, Haleon, during transition. This operating model change is profit neutral.

REVENUE SPLIT



NRT	₹ 656 Cr
↓ 2%YoY	↓ 6% QoQ
Germany	₹ 407 Cr
↑ 29%YoY	↑ 6% QoQ
UK	₹ 231 Cr
↑ 33%YoY	↑ 1% QoQ
Others	₹ 149 Cr
↑ 29%YoY	↑ 4% QoQ

Q1FY27 PSAI Performance


Margin impacted by semaglutide API related impact



Revenues
₹ 852 Cr

↑ 4%YoY ↓ 7%QoQ

Historical Revenues (₹ Cr)



GROSS MARGIN

4.5% vs 13.2%
Q1FY27 vs Q1FY26

DMF FILINGS

38
Q1FY27

US DMF FILINGS

NIL
Q1FY27

KEY UPDATES

- PSAI revenues grew YoY growth due to **momentum in CDMO business** and favourable forex, offset by lower API volume uptake.
- Excluding the **semaglutide API related impact**, PSAI gross margins at **12.9%** (vs. reported 4.5%).

In Summary

A diversified business model with broad based levers



Strengthen Core Businesses, build future growth drivers
(Peptides, Biosimilars, Consumer Health, Innovative Assets)



Advance key products
(Semaglutide including resumption of supplies, Abatacept)



Drive efficiencies through better operational leverage



Augment organic growth with **M&A and In-Licensing**



Enhance capabilities – People, Digital, Processes



Focus on **quality, compliance** and **sustainability**

Dr.Reddy's



About Key Metrics and Non-GAAP Financial Measures

This press presentation contains non-GAAP financial measures within the meaning of Regulation G and Item 10(e) of Regulation S-K. Such non-GAAP financial measures are measures of our historical performance, financial position or cash flows that are adjusted to exclude or include amounts, as the case may be, from the most directly comparable financial measure calculated and presented in accordance with IFRS.

The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with IFRS. Our non-GAAP financial measures are not based on any comprehensive set of accounting rules or principles. These measures may be different from non-GAAP financial measures used by other companies, limiting their usefulness for comparison purposes.

We believe these non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance, and allow for greater transparency with respect to key metrics used by management in operating our business.

For more information on our non-GAAP financial measures and a reconciliation of GAAP to non-GAAP measures, please refer to "Reconciliation of GAAP to Non-GAAP Results" table in the press release.



Good Health Can't Wait.